143 related articles for article (PubMed ID: 14770271)
1. Translational research using the sodium/iodide symporter in imaging and therapy.
Chung JK; Kang JH
Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):799-802. PubMed ID: 14770271
[No Abstract] [Full Text] [Related]
2. Overlooked contributions on sodium iodide symporter.
Dadachova E; Zuckier LS
J Nucl Med; 2003 Oct; 44(10):1707. PubMed ID: 14530492
[No Abstract] [Full Text] [Related]
3. Combining transfer of TTF-1 and Pax-8 gene: a potential strategy to promote radioiodine therapy of thyroid carcinoma.
Mu D; Huang R; Li S; Ma X; Lou C; Kuang A
Cancer Gene Ther; 2012 Jun; 19(6):402-11. PubMed ID: 22498723
[TBL] [Abstract][Full Text] [Related]
4. Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter.
Hsieh YJ; Ke CC; Liu RS; Wang FH; Tang KT; Chi CW; Chen FD; Lee CH
Anticancer Res; 2007; 27(4B):2515-22. PubMed ID: 17695547
[TBL] [Abstract][Full Text] [Related]
5. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
6. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
7. Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors.
Trouttet-Masson S; Selmi-Ruby S; Bernier-Valentin F; Porra V; Berger-Dutrieux N; Decaussin M; Peix JL; Perrin A; Bournaud C; Orgiazzi J; Borson-Chazot F; Franc B; Rousset B
Am J Pathol; 2004 Jul; 165(1):25-34. PubMed ID: 15215159
[TBL] [Abstract][Full Text] [Related]
8. Requisites for successful theranostics with radionuclide-based reporter gene imaging.
Ahn BC
J Drug Target; 2014 May; 22(4):295-303. PubMed ID: 24417717
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
10. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter.
Gholami S; Haddad D; Chen CH; Chen NG; Zhang Q; Zanzonico PB; Szalay AA; Fong Y
Surgery; 2011 Dec; 150(6):1040-7. PubMed ID: 22136819
[TBL] [Abstract][Full Text] [Related]
11. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.
Boland A; Ricard M; Opolon P; Bidart JM; Yeh P; Filetti S; Schlumberger M; Perricaudet M
Cancer Res; 2000 Jul; 60(13):3484-92. PubMed ID: 10910060
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene.
Lee YJ; Chung JK; Shin JH; Kang JH; Jeong JM; Lee DS; Lee MC
Thyroid; 2004 Nov; 14(11):889-95. PubMed ID: 15671766
[TBL] [Abstract][Full Text] [Related]
14. The feasibility of using a baculovirus vector to deliver the sodium-iodide symporter gene as a reporter.
Zhou X; Li B; Wang J; Yin H; Zhang Y
Nucl Med Biol; 2010 Apr; 37(3):299-308. PubMed ID: 20346869
[TBL] [Abstract][Full Text] [Related]
15. Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene.
Kim YH; Youn H; Na J; Hong KJ; Kang KW; Lee DS; Chung JK
Theranostics; 2015; 5(1):86-96. PubMed ID: 25553100
[TBL] [Abstract][Full Text] [Related]
16. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
[TBL] [Abstract][Full Text] [Related]
17. Functional activity of human sodium/iodide symporter in tumor cell lines.
Petrich T; Knapp WH; Pötter E
Nuklearmedizin; 2003 Feb; 42(1):15-8. PubMed ID: 12601449
[TBL] [Abstract][Full Text] [Related]
18. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Gene Ther; 2006 Jan; 13(1):60-6. PubMed ID: 16121204
[TBL] [Abstract][Full Text] [Related]
19. A perspective view of sodium iodide symporter research and its clinical implications.
Riesco-Eizaguirre G; Santisteban P
Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
